KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Operating Leases (2019 - 2025)

Neogenomics' Operating Leases history spans 7 years, with the latest figure at $67.6 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 11.11% year-over-year to $67.6 million; the TTM value through Dec 2025 reached $67.6 million, up 11.11%, while the annual FY2025 figure was $67.6 million, 11.11% up from the prior year.
  • Operating Leases reached $67.6 million in Q4 2025 per NEO's latest filing, up from $64.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $73.4 million in Q1 2022 to a low of $49.6 million in Q2 2021.
  • Average Operating Leases over 5 years is $65.1 million, with a median of $66.0 million recorded in 2023.
  • Peak YoY movement for Operating Leases: soared 70.91% in 2021, then decreased 12.01% in 2023.
  • A 5-year view of Operating Leases shows it stood at $72.3 million in 2021, then decreased by 4.62% to $69.0 million in 2022, then fell by 1.57% to $67.9 million in 2023, then dropped by 10.36% to $60.8 million in 2024, then increased by 11.11% to $67.6 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Operating Leases are $67.6 million (Q4 2025), $64.3 million (Q3 2025), and $66.6 million (Q2 2025).